Diagnostic Ventures was founded in Utah in 2022 with a singular focus: fundamentally changing how we diagnose infectious diseases. Born out of over five years of rigorous research at Brigham Young University and backed by $5.2M in funding from the National Institutes of Health, our foundational technology represents a leap forward in rapid diagnostics.
Today, armed with a proprietary diagnostic platform and a team of recognized clinical and commercial leaders, we are actively challenging the status quo. We aren't just optimizing tools—we are building the advanced systems necessary to drastically improve patient outcomes and solve healthcare's most complex diagnostic challenges.
Solving healthcare's deadliest diagnostic challenges by pioneering advanced, rapid testing systems that eliminate the wait for effective patient treatment.
Built on a foundation of rigorous academic discovery and proven clinical execution, our team brings centuries of collective expertise to the frontline of medicine. We have turned our focus toward pioneering the advanced rapid diagnostics necessary to eradicate sepsis and redefine acute patient care.
